Maria Luisa Garo, Petra Petranović Ovčariček, Stefano Fanti, Luca Giovanella
{"title":"[225Ac]Ac-PSMA用于治疗转移性去势抵抗性前列腺癌：系统综述和荟萃分析。","authors":"Maria Luisa Garo, Petra Petranović Ovčariček, Stefano Fanti, Luca Giovanella","doi":"10.1111/eci.14358","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Approximately 10%-20% of prostate cancers progress to metastatic and castration-resistant forms (mCRPC). Radioligand (RLT) therapy with [<sup>177</sup>Lu]Lu-prostate-specific membrane antigen (PSMA) is an approved treatment for metastasized mCRPC. Moreover, Actinium-225 (<sup>225</sup>Ac), an alpha-emitter isotope, has also been used to label PSMA and, recently, to treat mCRPC patients with encouraging results. However, robust clinical data on [<sup>225</sup>Ac]Ac-PSMA therapy and its comparison with [<sup>177</sup>Lu]Lu-PSMA are still limited. Our aim was to evaluate the role of [<sup>225</sup>Ac]Ac-PSMA in treating mCRPC and compare it with conventional [<sup>177</sup>Lu]Lu-PSMA therapy.</p><p><strong>Methods: </strong>A systematic search was performed in PubMed, Web of Science, Scopus and the Cochrane Register of Controlled Trials from June 2023 to January 2024. This work was conducted in accordance with PRISMA guidelines.</p><p><strong>Results: </strong>After screening and study selection according to PRISMA guidelines, 11 studies were included, 9 of which focused on [<sup>225</sup>Ac]Ac-PSMA only and two on tandem therapy ([<sup>225</sup>Ac]Ac-PSMA/[<sup>177</sup>Lu]Lu-PSMA). Overall, the pooled proportion of PSA decline in patients was .85 (95% CI: .79-.91, p < .001); patients pretreated with [<sup>177</sup>Lu]Lu-PSMA achieved a pooled proportion of PSA decline of .90 (95% CI: .82-.97, p < .001). In patients treated with tandem therapy, PSA decline was observed in approximately 90% of them, while PSA response rates above 50% ranged from 53.3% to 65%. Xerostomia was the most frequently reported side effect, along with anaemia, thrombocytopenia and nephrotoxicity.</p><p><strong>Conclusions: </strong>Overall, the main results of our study showed that [<sup>225</sup>Ac]Ac-PSMA-617 had a significant therapeutic effect on mCRPC with an acceptable toxicity level. The latter, however, appears greater than with [<sup>177</sup>Lu]Lu-PSMA-617. In future studies, an adequate analysis of the incidence of side effects associated with [<sup>225</sup>Ac]Ac-PSMA should be performed to evaluate the role of cumulative toxicity of earlier treatments and the higher frailty of heavily pretreated patients.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e14358"},"PeriodicalIF":4.4000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[<sup>225</sup>Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.\",\"authors\":\"Maria Luisa Garo, Petra Petranović Ovčariček, Stefano Fanti, Luca Giovanella\",\"doi\":\"10.1111/eci.14358\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Approximately 10%-20% of prostate cancers progress to metastatic and castration-resistant forms (mCRPC). Radioligand (RLT) therapy with [<sup>177</sup>Lu]Lu-prostate-specific membrane antigen (PSMA) is an approved treatment for metastasized mCRPC. Moreover, Actinium-225 (<sup>225</sup>Ac), an alpha-emitter isotope, has also been used to label PSMA and, recently, to treat mCRPC patients with encouraging results. However, robust clinical data on [<sup>225</sup>Ac]Ac-PSMA therapy and its comparison with [<sup>177</sup>Lu]Lu-PSMA are still limited. Our aim was to evaluate the role of [<sup>225</sup>Ac]Ac-PSMA in treating mCRPC and compare it with conventional [<sup>177</sup>Lu]Lu-PSMA therapy.</p><p><strong>Methods: </strong>A systematic search was performed in PubMed, Web of Science, Scopus and the Cochrane Register of Controlled Trials from June 2023 to January 2024. This work was conducted in accordance with PRISMA guidelines.</p><p><strong>Results: </strong>After screening and study selection according to PRISMA guidelines, 11 studies were included, 9 of which focused on [<sup>225</sup>Ac]Ac-PSMA only and two on tandem therapy ([<sup>225</sup>Ac]Ac-PSMA/[<sup>177</sup>Lu]Lu-PSMA). Overall, the pooled proportion of PSA decline in patients was .85 (95% CI: .79-.91, p < .001); patients pretreated with [<sup>177</sup>Lu]Lu-PSMA achieved a pooled proportion of PSA decline of .90 (95% CI: .82-.97, p < .001). In patients treated with tandem therapy, PSA decline was observed in approximately 90% of them, while PSA response rates above 50% ranged from 53.3% to 65%. Xerostomia was the most frequently reported side effect, along with anaemia, thrombocytopenia and nephrotoxicity.</p><p><strong>Conclusions: </strong>Overall, the main results of our study showed that [<sup>225</sup>Ac]Ac-PSMA-617 had a significant therapeutic effect on mCRPC with an acceptable toxicity level. The latter, however, appears greater than with [<sup>177</sup>Lu]Lu-PSMA-617. In future studies, an adequate analysis of the incidence of side effects associated with [<sup>225</sup>Ac]Ac-PSMA should be performed to evaluate the role of cumulative toxicity of earlier treatments and the higher frailty of heavily pretreated patients.</p>\",\"PeriodicalId\":12013,\"journal\":{\"name\":\"European Journal of Clinical Investigation\",\"volume\":\" \",\"pages\":\"e14358\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-11-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/eci.14358\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.14358","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
[225Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Background: Approximately 10%-20% of prostate cancers progress to metastatic and castration-resistant forms (mCRPC). Radioligand (RLT) therapy with [177Lu]Lu-prostate-specific membrane antigen (PSMA) is an approved treatment for metastasized mCRPC. Moreover, Actinium-225 (225Ac), an alpha-emitter isotope, has also been used to label PSMA and, recently, to treat mCRPC patients with encouraging results. However, robust clinical data on [225Ac]Ac-PSMA therapy and its comparison with [177Lu]Lu-PSMA are still limited. Our aim was to evaluate the role of [225Ac]Ac-PSMA in treating mCRPC and compare it with conventional [177Lu]Lu-PSMA therapy.
Methods: A systematic search was performed in PubMed, Web of Science, Scopus and the Cochrane Register of Controlled Trials from June 2023 to January 2024. This work was conducted in accordance with PRISMA guidelines.
Results: After screening and study selection according to PRISMA guidelines, 11 studies were included, 9 of which focused on [225Ac]Ac-PSMA only and two on tandem therapy ([225Ac]Ac-PSMA/[177Lu]Lu-PSMA). Overall, the pooled proportion of PSA decline in patients was .85 (95% CI: .79-.91, p < .001); patients pretreated with [177Lu]Lu-PSMA achieved a pooled proportion of PSA decline of .90 (95% CI: .82-.97, p < .001). In patients treated with tandem therapy, PSA decline was observed in approximately 90% of them, while PSA response rates above 50% ranged from 53.3% to 65%. Xerostomia was the most frequently reported side effect, along with anaemia, thrombocytopenia and nephrotoxicity.
Conclusions: Overall, the main results of our study showed that [225Ac]Ac-PSMA-617 had a significant therapeutic effect on mCRPC with an acceptable toxicity level. The latter, however, appears greater than with [177Lu]Lu-PSMA-617. In future studies, an adequate analysis of the incidence of side effects associated with [225Ac]Ac-PSMA should be performed to evaluate the role of cumulative toxicity of earlier treatments and the higher frailty of heavily pretreated patients.
期刊介绍：
EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
